Eisai and Biogen begin application process for second Alzheimer's drug

Lecanemab, which is being developed as a treatment for Alzheimer's disease by Eisai and Biogen, has been sent to the FDA through a "rolling submission" process under an accelerated approval pathway.


Eisai and Biogen are now making another attempt to tackle Alzheimer's disease, initiating a "rolling submission" process at the US Food and Drug Administration (FDA) of the drug lecanemab, the companies inform in a press release.

Like the company's other Alzheimer's drug, Aduhelm, which was FDA approved earlier this year, lecanemab is an antibody targeting the amyloid beta protein. In theory, by breaking down the protein plaques, the antibody should slow down the progression of the disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs